Parth Rali is a Respiratory physician affiliated with Temple University Hospital. OpenAlex indexes 175 publications with 2,984 citations (h-index 18); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3401 N Broad St
Philadelphia, PA 191405103
Telephone
215-707-5864Registry record last updated 21 Jul 2022.
Clinical trials
- The RESCUE II Study. The Bashir™ Endovascular Catheter (BEC),
Sponsor: Temple University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Stryker CorporationProgram year202522 payments$39,511openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year202521 payments$11,451openpaymentsdata.cms.gov ↗
- United Therapeutics CorporationProgram year202512 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
61.6%Corticosteroid20.3%Trelegy Ellipta61%Breo Ellipta30%Symbicort9%Part D<11 patientsbeta2-Adrenergic Agonist19%Albuterol Sulfate Hfa91%Ventolin Hfa9%Part D<11 patients+ 7 more classes in this area
Metabolism & gastrointestinal
7.8%Corticosteroid5.8%Prednisone100%Part D≥25 patientsProton pump inhibitor2%Omeprazole100%Part D<11 patientsCardiovascular
7.1%Activin Signaling Inhibitor4.9%Winrevair100%Part D<11 patientsLoop diuretic2.1%Furosemide100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Impact of reperfusion therapies on clot resolution and long-term outcomes in patients with pulmonary embolism
Journal of Vascular Surgery Venous and Lymphatic Disorders
2024 - Pulmonary Vasodilator Therapy Is Associated with Decreased Mortality in Patients with Chronic Lung Disease and Severe Pulmonary Hypertension
Journal of Cardiovascular Development and Disease
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Forfia, MD
Temple University Hospital
Edmond Cronin, MB, BCH, BAO, MRCPI
Temple University Hospital
Daniel Eun, MD
Temple University Hospital
Glenn Isaacson, MD
Temple University Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”